Prosonix and UCB extend codevelopment agreement
The renewal of the Agreement follows successful proof of concept and initial proof of process studies on two of UCB's lead pharmaceutical products, and represents the culmination of almost three years of collaborative r&d effort between the parties.
To enable further scale up and clinical development activities to be undertaken by UCB, Prosonix has provided a bespoke multipurpose Prosonitron sonocrystallisation reactor system that will be utilised in the cGMP manufacturing facilities at UCB's Braine l'Alleud site.
Prosonix sonocrystallization technology works by controlling and actively manipulating nucleation and subsequent crystal growth behaviour that is fundamental to the control of physical form and the improvement of a crystallisation process. An attractive feature of the technology is its scale-out nature, such that it can be applied at any stage and at any time across a product pipeline from early laboratory studies through to full industrialisation.
'With the high added-value nature of the products and stringent requirements for the control of all aspects of physical form, pharmaceuticals represent a natural and core market segment for Prosonix' proprietary sonocrystallisation technology,' said David Hipkiss, ceo of Prosonix. 'UCB's reputation to be early adopters of innovative new technologies coupled to its willingness to see these through to filing and full commercial operation makes it an ideal partner.'